Moderna Stock News

The coronavirus variant has quickly become dominant in many parts of the world, driving up infections and straining healthcare systems.

Moderna: The booster specifically targeting Omicron will therefore be evaluated as both a third and a fourth dose

Moderna has started testing an omicron-specific booster shot in adults, the company announced Wednesday.The trial, which will include several hundred people at two dozen sites across the U.S., comes as companies and health officials grapple with a…

Moderna CEO Stéphane Bancel previously projected the Omicron-specific vaccine booster to be available as early as this fall.

Moderna has dosed the first patient in a phase 2 trial evaluating an Omicron variant-specific COVID-19 vaccine.

Moderna said it''s moving ahead with an omicron-specific booster shot on Wednesday. The news could prod Moderna stock.

The first participant in the trial has already received a dose of the omicron-specific booster shot, according to Moderna.

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

Following a stock drop of ~39% over the last month alone, Deutsche Bank has upgraded shares of Moderna citing a more reasonable valuation.

Pfizer Begins Human Trials For New Omicron Vaccine As US Cases Tumble Pfizer and its partner BioNTech just launched the first human trials of their revised COVID vaccine which has been adapted to try and provide better protection against the omicron variant. Shortly after the emergence of omicron in late November, Pfizer and its rivals all promised to produce another generation of vaccines, claiming they could have them ready within three months. So far at least, that timeline appears mostly on track. However, an even more important question for Pfizer might be this: who will even need these jabs when they''re ready, since it looks like the omicron wave numbers will have finally tapered off by the time the trials are completed. At any rate, the two firms said Tuesday they had begun enrolling adults ages 18 to 55 for trials taking place in the US and South Africa. The trials will seek to examine the safety, tolerability and, most importantly, the immune response generated by the new vaccines, per WSJ.

Bank of America upgraded its rating on pharma and biotech company Moderna from underperform to neutral along with a new price target of $180 (up from $135) according to a recent BofA Global Research report. BofA cited a more reasonable valuation that has come about as being the main reason for the upgrade.

"Wake Up Welcome To Reality In 2022" Authored by Bill Blain via MorningPorridge.com, Fair fa yer honest sonsie face, great chieftain o the puddin race . After yesterdays dramatic market roller-coaster, traders are wondering if its a buy-the-dip moment. They probably will. But the narrative has reversed. The improbable tech stocks into substantial correction territory have a considerable way still to fall if history is any guide. Yesterday, was an extraordinary day. which we will all-to-soon forget. As European markets closed last night it looked like markets had surrendered, down some 5%. More than a few chums were wondering if this is it . Apparently, the massive volumes in the morning were driven by retail investors who, after fretting about their loss-making positions for the whole weekend, decided to dump stock. In the afternoon, the selling reversed as brave buyers reckoned they were smarter, reckoned stocks looked cheap, and for all the usual reasons the market recovered one of the biggest upside reversals in recent history Volatility is back with a vengeance.

"Volatility Is Back": Futures Resume Sliding After Historic Rollercoaster Reversal Following one of the greatest intraday market reversals in history, US index futures resumed their decline led by the Nasdaq, signaling more pain for richly valued technology shares as investors braced for the highly anticipated Fed meeting and a flurry of earnings as geopolitical tensions between Russia and Ukraine persisted. Companies including GE, J&J, Verizon and Microsoft report earnings on Tuesday, as the Fed starts a two-day meeting. As of 7:30am ET, emini S&P futures were down 60 points or 1.36% to 4,343, Nasdaq futures were down 1.88% or 272 points and Dow futures were down 236 points or 0.68%. The VIX was at 33, after swinging between 29 and 39 on Monday; 10Y Treasury yields were unchanged at 1.77% and the dollar gained. US equities swung in a rollercoaster of volatility on Monday as both underlying gauges had erased intraday losses to end the session slightly higher as dip-buyers came in. According to JPM''s trading desk, yesterday''s 5% reversal in the Nasdaq is an uncommon occurrence: "If you exclude March 2020, yesterday was the 7th 5%+ NDX reversal since GFC.

The bullish case for owning COVID-19 vaccine makers is weakening as much of the world throws in the towel on trying to curb the spread of the coronavirus.

The day''s most volatile stocks included Moderna, Nvidia and Netflix.